Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors

Chan Shen, Ying Xu, Arvind Dasari, Ya Chen Tina Shih, James C. Yao

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction. Octreotide long-acting repeatable (LAR) is approved for the management of carcinoid syndromes and may improve progression-free survival of patients with well-differentiated neuroendocrine tumors (NETs). It is unknown whether the dosage of octreotide LAR affects survival. This paper evaluates the association between initial octreotide LAR dosage and overall survival of elderly patients with NETs. Patients and Methods. Patients with distant-stage NET diagnosed between January 1999 and December 2009 who received octreotide LAR treatment within 12 months of diagnosis were identified fromthe Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Those under age 65 years, enrolled in health maintenance organizations, or without continuous enrollment in Medicare Parts A and B were excluded. We compared the 5-year survival of patients with NET based on dose per 28 days averaged over the initial 3 months: low (≤20 mg); medium (21–30 mg); high (.30 mg). Kaplan-Meier estimations and Cox proportional hazard modeling were used to examine the association between octreotide LAR dose and survival. Results. Among 222 patients with distant-stage NET who received octreotide LAR treatment, 81 (36%) received a low dosage,82(37%) receivedamediumdosage, andonly59(27%) received a high dosage. Multivariate analysis showed that compared with a medium octreotide LAR dose, a low dosage was associated with significantly worse survival (hazard ratio [HR]: 2.00; p 5 .001), whereas a high initial dosage (HR: 1.09; p 5 .719) did not show additional survival benefits over that observed with a medium dosage. Conclusion. This population-based study suggests potential survival benefits for octreotide LAR provided within 12 months of diagnosis at a dosage of 21–30 mg among elderly patients with distant-stage NET.

Original languageEnglish (US)
Pages (from-to)308-313
Number of pages6
JournalOncologist
Volume21
Issue number3
DOIs
StatePublished - Feb 24 2016

Fingerprint

Octreotide
Neuroendocrine Tumors
Survival
Medicare Part A
Medicare Part B
Health Maintenance Organizations
Carcinoid Tumor
Medicare
Disease-Free Survival
Epidemiology
Multivariate Analysis
Databases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shen, Chan ; Xu, Ying ; Dasari, Arvind ; Tina Shih, Ya Chen ; Yao, James C. / Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. In: Oncologist. 2016 ; Vol. 21, No. 3. pp. 308-313.
@article{54c66dc1aa7f4cbdaa81d8293e9adf44,
title = "Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors",
abstract = "Introduction. Octreotide long-acting repeatable (LAR) is approved for the management of carcinoid syndromes and may improve progression-free survival of patients with well-differentiated neuroendocrine tumors (NETs). It is unknown whether the dosage of octreotide LAR affects survival. This paper evaluates the association between initial octreotide LAR dosage and overall survival of elderly patients with NETs. Patients and Methods. Patients with distant-stage NET diagnosed between January 1999 and December 2009 who received octreotide LAR treatment within 12 months of diagnosis were identified fromthe Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Those under age 65 years, enrolled in health maintenance organizations, or without continuous enrollment in Medicare Parts A and B were excluded. We compared the 5-year survival of patients with NET based on dose per 28 days averaged over the initial 3 months: low (≤20 mg); medium (21–30 mg); high (.30 mg). Kaplan-Meier estimations and Cox proportional hazard modeling were used to examine the association between octreotide LAR dose and survival. Results. Among 222 patients with distant-stage NET who received octreotide LAR treatment, 81 (36{\%}) received a low dosage,82(37{\%}) receivedamediumdosage, andonly59(27{\%}) received a high dosage. Multivariate analysis showed that compared with a medium octreotide LAR dose, a low dosage was associated with significantly worse survival (hazard ratio [HR]: 2.00; p 5 .001), whereas a high initial dosage (HR: 1.09; p 5 .719) did not show additional survival benefits over that observed with a medium dosage. Conclusion. This population-based study suggests potential survival benefits for octreotide LAR provided within 12 months of diagnosis at a dosage of 21–30 mg among elderly patients with distant-stage NET.",
author = "Chan Shen and Ying Xu and Arvind Dasari and {Tina Shih}, {Ya Chen} and Yao, {James C.}",
year = "2016",
month = "2",
day = "24",
doi = "10.1634/theoncologist.2015-0381",
language = "English (US)",
volume = "21",
pages = "308--313",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. / Shen, Chan; Xu, Ying; Dasari, Arvind; Tina Shih, Ya Chen; Yao, James C.

In: Oncologist, Vol. 21, No. 3, 24.02.2016, p. 308-313.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors

AU - Shen, Chan

AU - Xu, Ying

AU - Dasari, Arvind

AU - Tina Shih, Ya Chen

AU - Yao, James C.

PY - 2016/2/24

Y1 - 2016/2/24

N2 - Introduction. Octreotide long-acting repeatable (LAR) is approved for the management of carcinoid syndromes and may improve progression-free survival of patients with well-differentiated neuroendocrine tumors (NETs). It is unknown whether the dosage of octreotide LAR affects survival. This paper evaluates the association between initial octreotide LAR dosage and overall survival of elderly patients with NETs. Patients and Methods. Patients with distant-stage NET diagnosed between January 1999 and December 2009 who received octreotide LAR treatment within 12 months of diagnosis were identified fromthe Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Those under age 65 years, enrolled in health maintenance organizations, or without continuous enrollment in Medicare Parts A and B were excluded. We compared the 5-year survival of patients with NET based on dose per 28 days averaged over the initial 3 months: low (≤20 mg); medium (21–30 mg); high (.30 mg). Kaplan-Meier estimations and Cox proportional hazard modeling were used to examine the association between octreotide LAR dose and survival. Results. Among 222 patients with distant-stage NET who received octreotide LAR treatment, 81 (36%) received a low dosage,82(37%) receivedamediumdosage, andonly59(27%) received a high dosage. Multivariate analysis showed that compared with a medium octreotide LAR dose, a low dosage was associated with significantly worse survival (hazard ratio [HR]: 2.00; p 5 .001), whereas a high initial dosage (HR: 1.09; p 5 .719) did not show additional survival benefits over that observed with a medium dosage. Conclusion. This population-based study suggests potential survival benefits for octreotide LAR provided within 12 months of diagnosis at a dosage of 21–30 mg among elderly patients with distant-stage NET.

AB - Introduction. Octreotide long-acting repeatable (LAR) is approved for the management of carcinoid syndromes and may improve progression-free survival of patients with well-differentiated neuroendocrine tumors (NETs). It is unknown whether the dosage of octreotide LAR affects survival. This paper evaluates the association between initial octreotide LAR dosage and overall survival of elderly patients with NETs. Patients and Methods. Patients with distant-stage NET diagnosed between January 1999 and December 2009 who received octreotide LAR treatment within 12 months of diagnosis were identified fromthe Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Those under age 65 years, enrolled in health maintenance organizations, or without continuous enrollment in Medicare Parts A and B were excluded. We compared the 5-year survival of patients with NET based on dose per 28 days averaged over the initial 3 months: low (≤20 mg); medium (21–30 mg); high (.30 mg). Kaplan-Meier estimations and Cox proportional hazard modeling were used to examine the association between octreotide LAR dose and survival. Results. Among 222 patients with distant-stage NET who received octreotide LAR treatment, 81 (36%) received a low dosage,82(37%) receivedamediumdosage, andonly59(27%) received a high dosage. Multivariate analysis showed that compared with a medium octreotide LAR dose, a low dosage was associated with significantly worse survival (hazard ratio [HR]: 2.00; p 5 .001), whereas a high initial dosage (HR: 1.09; p 5 .719) did not show additional survival benefits over that observed with a medium dosage. Conclusion. This population-based study suggests potential survival benefits for octreotide LAR provided within 12 months of diagnosis at a dosage of 21–30 mg among elderly patients with distant-stage NET.

UR - http://www.scopus.com/inward/record.url?scp=84960499696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960499696&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0381

DO - 10.1634/theoncologist.2015-0381

M3 - Article

C2 - 26911407

AN - SCOPUS:84960499696

VL - 21

SP - 308

EP - 313

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -